• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Metformin alleviates inflammatory response in non-alcoholic steatohepatitis by restraining signal transducer and activator of transcription 3-mediated autophagy inhibition in  vitro and in vivo.
In conclusion, this study demonstrated that metformin alleviated the inflammatory response in the liver and the hepatocyte of the NASH model via STAT3-mediated autophagy induction. This mechanism provides a strategy for targeting the NASH inflammatory response. PMID: 30935688 [PubMed - as supplied by publisher]
Source: Biochemical and Biophysical Research communications - March 28, 2019 Category: Biochemistry Authors: Li YL, Li XQ, Wang YD, Shen C, Zhao CY Tags: Biochem Biophys Res Commun Source Type: research

Metformin ameliorates TGF- β1-induced osteoblastic differentiation of human aortic valve interstitial cells by inhibiting β-catenin signaling.
In conclusion, our results suggest a beneficial effect of metformin based on the prevention of osteoblastic differentiation of human AVICs via inhibition of β-catenin, which indicates the therapeutic potential of metformin for CAVD. PMID: 29679571 [PubMed - as supplied by publisher]
Source: Biochemical and Biophysical Research communications - April 18, 2018 Category: Biochemistry Authors: Fayuan L, Chong C, Qinyu W, Shi Jiawei, Huadong L, Nianguo D Tags: Biochem Biophys Res Commun Source Type: research

TRAIL restores DCA/metformin-mediated cell death in hypoxia.
Abstract Previous studies have shown that hypoxia can reverse DCA/metformin-induced cell death in breast cancer cells. Therefore, targeting hypoxia is necessary for therapies targeting cancer metabolism. In the present study, we found that TRAIL can overcome the effect of hypoxia on the cell death induced by treatment of DCA and metformin in breast cancer cells. Unexpectedly, DR5 is upregulated in the cells treated with DCA/metformin, and sustained under hypoxia. Blocking DR5 by siRNA inhibited DCA/metformin/TRAIL-induced cell death, indicating that DR5 upregulation plays an important role in sensitizing cancer ce...
Source: Biochemical and Biophysical Research communications - August 24, 2016 Category: Biochemistry Authors: Hong SE, Kim CS, An S, Kim HA, Hwang SG, Song JY, Lee JK, Hong J, Kim JI, Noh WC, Jin HO, Park IC Tags: Biochem Biophys Res Commun Source Type: research

Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor.
Abstract Metformin is a biguanide drug that is widely used for the treatment of type 2 diabetes. Recent studies have shown that metformin inhibits cancer cell proliferation and tumor growth both in vitro and in vivo. The anti-tumor mechanisms of metformin include activation of the AMP-activated protein kinase/mTOR pathway and direct inhibition of insulin/insulin-like growth factor (IGF)-mediated cellular proliferation. However, the anti-tumor mechanism in prostate cancer remains unclear. Because activation of the IGF-1 receptor (IGF-1R) is required for prostate cell proliferation, IGF-1R inhibitors may be of the...
Source: Biochemical and Biophysical Research communications - April 7, 2015 Category: Biochemistry Authors: Kato H, Sekine Y, Furuya Y, Miyazawa Y, Koike H, Suzuki K Tags: Biochem Biophys Res Commun Source Type: research